Scientific Computing World reports that Isogenica has launched a collaborative joint venture with Biolauncher and Cresset Biomolecular Discovery to develop an “end-to-end therapeutic discovery platform.” Under the terms of the collaboration, the parties will integrate their expertise in peptide library design, evolutionary screening, next-generation sequencing, structural analytics, and molecular-field-based computational chemistry to identify active compounds against high-value therapeutic targets.
We are excited by the potential to integrate cutting-edge molecular biology with state-of-the-art computational biology and chemistry tools to develop small molecule drugs against novel targets using the combined expertise of the businesses,’ commented Kevin Matthews, CEO at Isogenica. ‘The industry needs to leverage the significant investment in individual platform technologies to address the innovation gap and deliver shareholder value from therapeutic research and development.’
Read the Full Story.
